Despite "continued progress" during a drug delivery collaboration with Johnson & Johnson spinoff Zosano, Novo Nordisk has discontinued a partnership, Zosano said Monday in a statement.
China's Guangxi Wuzhou Pharmaceutical bought a 10% stake in Israel's Oramed Pharma for $52 million as well as China rights to two diabetes treatments, Reuters reported. The deal builds on a December 2014 investment of $5 million for a 7% stake in a private placement.
China's Guangxi Wuzhou Zhongheng Group disclosed that it intends to purchase a 10% stake in Israeli pharma company Oramed for $52 million, in return for exclusive Chinese distribution rights to its oral insulin following regulatory approval, according to a briefing from Reuters.
Quest Diagnostics is charging full speed ahead with its previously announced joint venture with global CRO Quintiles, launching the companies' new business, dubbed Q2 Solutions, to provide lab services for clinical trials and to expand its diagnostics footprint.
Quintiles and Quest Diagnostics rolled out Q2 Solutions, a $575 million joint venture that pairs the CRO's experience running studies with the latter company's expertise in lab tests.
GVK BioSciences, an Indian CRO under fire from European regulators, has signed a deal with Australia's Akaal Pharma to help the company move its in-development psoriasis treatment into mid-stage trials.
Covance, now a division of LabCorp, has signed a two-year partnership with the Society for Clinical Research Sites, joining a growing list of CROs working to improve communication between sponsors and investigators.
The government of Equatorial Guinea has teamed up with Marathon Oil, Noble Energy and AMPCO to sponsor the development of the Sanaria PfSPZ vaccine against malaria. The $48.5 million in funding includes support for clinical trials from 2015 to 2018, Sanaria said in a statement.
The API of GlaxoSmithKline's HIV therapy Tivicay (dolutegravir) will be made in China by Shanghai-based Desano Pharmaceuticals under a deal with the British drug maker's ViiV Healthcare arm, according to a press release.
Electronic medical records company Allscripts took a $200 million (or 10%) stake in drug discovery company NantHealth to strengthen their alliance focused on personalized medicine in the cancer treatment arena.